A promising novel therapeutic strategy for CLL is to target the apoptotic machinery directly by the so-called BH3-mimetics, i.e. BCL2-specific compound ABT-199 or venetoclax. The gene discussed is BCL2; the disease is B-cell chronic lymphocytic leukemia.